
The WHO's cancer agency, IARC, has classified Hydrochlorothiazide, Voriconazole, and Tacrolimus as Group 1 carcinogens in Volume 137 of its latest monographs.
Hydrochlorothiazide, used for hypertension, was upgraded from Group 2B to Group 1 due to evidence linking its prolonged use to non-melanoma skin cancers.
Health experts in Hyderabad warn patients not to stop medication abruptly, noting that uncontrolled hypertension poses a greater immediate risk than the long-term statistical cancer threat.